v3.19.3.a.u2

Commitments and Contingencies - Strategic Collaborations (Details) - PCV Agreement - USD ($) $ in Millions | Dec. 31, 2019 | Dec. 31, 2018 | Apr. 30, 2018 | Jun. 30, 2016
--- | --- | --- | --- | ---
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Budgeted amount |  |  |  | $ 250.0
PCV products |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Budgeted amount | $ 243.0 | $ 243.0 | $ 243.0 |

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Maximum Amount + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |